Verily secures USD 300m to scale AI health platform, signaling strategic shift from Alphabet

Verily Health Inc., a precision health technology company headquartered in Dallas, TX, has closed a USD 300 million investment round to fund the next phase of its AI-enabled health platform strategy. The Verily investment marks a structural shift for the company, which has transitioned from an LLC to a corporation under the new name Verily Health Inc., with Alphabet moving from a controlling stake to a significant minority position, the company said.

Series X Capital led the round, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other unnamed investors. Verily said it plans to use the funds to accelerate its AI-native precision health platform and expand its capacity to help customers harmonize healthcare data and deploy actionable intelligence into research and care workflows. Stephen Gillett, Chairman and CEO, said the funding would support solutions that combine clinical and scientific rigor with AI.

Verily does not maintain a traditional drug development pipeline. The company operates as a data and technology platform provider rather than a therapeutic developer, with no registered clinical trials for novel drug candidates in current databases. Its Pre platform is designed to integrate and harmonize multimodal health data — including electronic health records, genomic data, wearable sensor outputs, and imaging — using AI and machine learning. The platform supports biomarker discovery, patient stratification, clinical trial optimization, and real-world evidence generation for pharmaceutical and academic partners.

The company has recently announced several commercial partnerships that illustrate this enabling role. These include a collaboration with Samsung’s Galaxy Watch to support biomarker development for life sciences customers through the Pre platform, and a strategic integration with Salesforce’s Agentforce Health for enterprise precision health solutions. Verily has also entered a research collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience focused on AI-powered research and care transformation.

Verily’s platform technology originated within Google’s corporate R&D infrastructure. The company was established in 2015 as a rebranding of Google Life Sciences and became one of Alphabet’s earliest independent subsidiaries. Its core AI, cloud computing, and data engineering capabilities were inherited from Google rather than licensed from academic institutions. Verily has augmented its platform through acquisitions, including SignalPath (clinical trial management, 2020), Ciitizen (patient health record aggregation, 2022), and Aria Pharmaceuticals, formerly Goldfinch Bio (computational drug discovery in kidney diseases, 2024). None of these originated as university spinouts.

Gillett joined Verily as CEO with a background in technology leadership. Series X Capital, which led the round, was established in collaboration with Google’s X, The Moonshot Factory, to scale technologies into commercial enterprises. Gideon Yu, Founder and Managing Partner of Series X Capital, said the firm was established to support companies emerging from X’s moonshot programs.

Details of previous funding rounds were not disclosed in the announcement. The USD 300 million round represents the first publicly announced financing since Verily’s corporate restructuring. Alphabet had previously funded Verily through its corporate treasury as part of its “Other Bets” portfolio since the company graduated from Google X approximately ten years ago.